Dougherty & Co Weighs in on Apollo Medical Holdings Inc’s Q3 2019 Earnings (NASDAQ:AMEH)

Apollo Medical Holdings Inc (NASDAQ:AMEH) – Investment analysts at Dougherty & Co issued their Q3 2019 earnings estimates for Apollo Medical in a research report issued on Tuesday, August 13th. Dougherty & Co analyst G. Mannheimer expects that the company will post earnings per share of $0.13 for the quarter.

A number of other brokerages also recently issued reports on AMEH. Zacks Investment Research downgraded shares of Apollo Medical from a “hold” rating to a “strong sell” rating in a research report on Friday, August 9th. TheStreet raised shares of Apollo Medical from a “d” rating to a “c-” rating in a research report on Friday, June 28th. Finally, ValuEngine raised shares of Apollo Medical from a “hold” rating to a “buy” rating in a report on Friday, August 2nd.

Shares of AMEH stock opened at $16.36 on Wednesday. Apollo Medical has a 1 year low of $13.36 and a 1 year high of $23.32. The firm has a fifty day moving average price of $15.33 and a 200-day moving average price of $17.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.00 and a quick ratio of 2.00. The company has a market cap of $525.93 million, a price-to-earnings ratio of 56.41, a PEG ratio of 4.93 and a beta of -0.80.

In other news, CEO Thomas S. Lam bought 6,900 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The stock was bought at an average price of $14.64 per share, with a total value of $101,016.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mark Fawcett bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The stock was purchased at an average cost of $14.13 per share, with a total value of $141,300.00. The disclosure for this purchase can be found here. Insiders purchased a total of 26,036 shares of company stock valued at $375,418 in the last ninety days. 11.83% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its holdings in Apollo Medical by 113.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,733 shares of the company’s stock worth $28,000 after buying an additional 922 shares during the period. Tower Research Capital LLC TRC lifted its stake in Apollo Medical by 1,518.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,414 shares of the company’s stock worth $57,000 after purchasing an additional 3,203 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Apollo Medical in the 1st quarter worth $106,000. Strs Ohio lifted its stake in Apollo Medical by 98.6% in the 1st quarter. Strs Ohio now owns 14,300 shares of the company’s stock worth $261,000 after purchasing an additional 7,100 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Apollo Medical by 52.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 19,822 shares of the company’s stock worth $332,000 after purchasing an additional 6,816 shares in the last quarter. 6.61% of the stock is owned by institutional investors.

Apollo Medical Company Profile

Apollo Medical Holdings, Inc, a physician-centric integrated population health management company, provides medical care services. The company offers care coordination services to principal constituents of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.

See Also: Understanding Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Apollo Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Medical and related companies with MarketBeat.com's FREE daily email newsletter.